Thomas Mürdter
Deputy Head at IKP; Research Group Leader Tumor Models & Microenvironment; Head of Chemical Analytics & Synthesis

Dr. Thomas Mürdter

Major Projects

  • Influence of pharmacogenetics on the metabolism of Selective Estrogen Receptor Modulators
  • Synthesis and analysis of phase I and II metabolites
  • Ex vivo models of human tumors

Major Networks and Collaborations

  • TAMENDOX: Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients

Extramural Funding

  • BMBF (Federal Ministry of Education and Research): Initiative Individualized Medicine: TAMENDOX
  • DFG (German Research Foundation): The role of agonistic metabolites in Tamoxifen resistance

Curriculum Vitae

Education and Professional Career

Since 1997

Scientist at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

1997

PhD in Chemistry. Thesis: Distribution, tumour selectivity, and bio-activation of doxorubicin in the isolated perfused human lung model.

1994-1997

PhD studies at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology

1992-1994

Deputy head of the Department of Polymer and Environmental Analysis at the Institute of Polymeric Sciences, Stuttgart, Germany

1991-1992

Research fellow at the Fraunhofer Institute for Interfacial Engineering and Biotechnology

1991

Diploma Thesis at the Department of Chemical Microbiology at the Fraunhofer Institute for Interfacial Engineering and Biotechnology: Degradation of trichloroethylene by the alcaligenes denitrificans ssp xylosoxidans strain JE95

1988-1991

    Graduate studies in Chemistry with elective subject Biochemistry at University of Stuttgart

1988

Industrial traineeship at PLIVA Ltd. Zagreb, Yugoslavia

1984-1987

Undergraduate studies in Chemistry at University of Stuttgart

Professional Memberships

Since 1998: Member of the DGTP (German Society of Toxicology and Pharmacology)